The Infection Genomics Programme investigates the common underpinning mechanisms of evolution, infection and resistance to therapy in viruses, bacteria and parasites. The Programme also focuses on the genetics of host response to infection and the role of the microbiota in health and disease.
The Infection Genomics Programme:
uses pathogen genomics and phylogenetics to understand transmission and evolution of diverse pathogens, and to discover determinants of host-interaction, virulence and evasion of antimicrobial drugs and vaccines.
uses host genetics in natural populations and engineered variation in model systems to identify variants underlying resistance and susceptibility to infectious agents, and validate these in model organisms and cellular systems.
combines variants from pathogen and host to interrogate host-pathogen interactions using functional genomic approaches.
uses metagenomics, large-scale culture and model murine systems to define the role of the microbiota in infectious and inflammatory diseases, particularly of the gut.
investigates the biology of the immune system in response to natural and vaccine stimulation.
develops tools and reference data sets (annotated genomes and functional genomics) for neglected and fastidious pathogens to enable research within and outside the Institute, with a focus on experimental manipulation and surface-protein interactions in Schistosoma and Trichuris.
focuses on the genetics and molecular biology of antimicrobial resistance, an area of key global concern, investigating common underpinning mechanisms of resistance to therapy.
We use large-scale pathogen genomics, analysing well-characterised population samples to discover the genetic basis of key phenotypes including host adaptation, virulence, transmission and escape from therapy. We incorporate novel microbial genetic association studies and use high-throughput approaches to validate pathogen phenotypes. We interrogate the contribution of the microbiota to health and disease using clinical samples, novel microbial culturing methods and germ-free models. We are establishing a project to understand the molecular basis of antibiotic resistance that will exploit microbial phylogeny and high-throughput phenotyping.
Our research in the host uses in vivo screens linked to human studies to identify and characterise novel host infection susceptibility loci for microbe-associated diseases. This Project employs targeted mutagenesis, humanised mice (genetics and microbiota) and single-cell genomics to analyse the effect of host variation on microbial infection. We are working closely with the Cellular Genetics Programme to model infection using human stem cell biology and associated differentiation and mutagenesis technologies. We contribute specific models (macrophages and organoids) and infection screens to that programme, and use these models in our own characterisation of susceptibility loci.
We are developing our vaccine-related research by focusing on the humoral immune response in terms of repertoire analysis and work on antibody function, linked to clinical studies on vaccination and pathogen challenge. This work draws on our links with the vaccine industry and the availability of modified mice harbouring genes encoding entire human antibody repertoires.
We analyse complex parasite genomes to provide high-quality reference genomes, and develop functional genomics (transcriptomics, mass spectrometry, recombinant protein libraries, host receptor identification etc.) for selected pathogens including Schistosoma and Trichuris. We have established components of the life cycle of these parasites in our laboratories to facilitate functional studies. We are creating sequence-based methodologies for characterising fastidious organisms present in complex materials, including clinical swabs and the environment.
To deliver our science, we work closley with the Human and Cellular Genetics Programmes and with key collaborators in UK Universities, the Wellcome Trust Overseas Units, and vaccine companies including The Hilleman Laboratories. We support the Centre for Genomic Pathogen Surveillance and UK health authorities in the clinical implementation of genomic approaches.
In addition to our core faculty, listed below, we also work with others including:
A free genome browser and annotation tool that allows visualisation of sequence features, next generation data and the results of analyses within the context of the sequence, and also its six-frame translation.
A Java application for displaying pairwise comparisons between two or more DNA sequences. It can be used to identify and analyse regions of similarity and difference between genomes and to explore conservation of synteny, in the context of the entire sequences and their annotation.
The broad aims of the Centre for Genomic Pathogen Surveillance are to provide data and tools for local, national and international utility focussed on antimicrobial resistance and genomic surveillance.
Our group consistis of a mix of genomic epidemiologists, computational biologists and web software engineers within The Centre for Genomic Pathogen Surveillance (CGPS) a collaboration with imperial College London.Within CGPS, broad aims are to provide data and tools for local, national and international utility focused on antimicrobial resistance and genomic surveillance. We are addressing the utility of large-scale structured pathogen surveys to provide contextual WGS datasets and population structure. Key aims are to enable the identification of high risk clones of public health importance, their risk assessment (eg resistance, virulence and transmissibility) and ultimately management.
The Microbial Pathogenesis team, under the leadership of Professor Gordon Dougan, is focusing on the genetic analysis of the interactions between bacteria and their hosts to shed light on how humans and other animals respond to infection.
The host-microbiota Interactions laboratory studies the mechanisms that underlie how micro-organisms in the gut, nasopharynx and uro-gential tract interact with their host during periods of health and disease. In particular the team seek to develop novel ways to treat diseases that are associated with unwanted imbalances in the micro-organism population.
The bacterial genomics and evolution team focuses primarily on using whole-genome sequencing approaches to study the patterns and drivers for historical and ongoing pathogen genome evolution. This is then combined with screens in whole cells or model organisms to understand the phenotypic consequences of those changes.
The Pathogen Informatics team develop and maintain software applications and systems to support the research activities of the pathogen group. We develop and maintain scalable and robust automated tools for sequence and annotation tracking and analysis and provide ad-hoc informatics support and training to the researchers in the pathogen group.
The activities of the team include anything from organising international travel itineraries, servicing multi-million pound collaboratorive grants and facilitating Faculty management meetings to organising hospitality and fielding day-to-day enquiries relating to specific projects, including sequencing.
New chlamydia drug targets discovered using CRISPR and stem cells
Based on ground-breaking research at the Wellcome Trust Sanger Institute into the role of the human microbiome in disease. Goal is to create the world’s leading company focused on microbiome biology and its use in medicine. Cambridge Innovation Capital and IP Group co-lead £8m funding round.
Online epidemic tracking tool embraces open data and collective intelligence to understand outbreaks
Researchers from the Wellcome Trust Sanger Institute and Imperial College London have developed Microreact, a free, real-time epidemic visualisation and tracking platform that has been used to monitor outbreaks of Ebola, Zika and antibiotic-resistant microbes